Compare Abeona Therapeutics Inc (ABEO) vs Figs Inc (FIGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Figs Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Figs Inc trades at $10.29 (market cap $1.65B). The key difference: Figs Inc is far larger — about 4.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FIGS | |
|---|---|---|
Market Cap | $373.32M | $1.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $17.12 |
52-Week Low | $4.17 | $5.81 |
Enterprise Value | $228.22M | $1.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FIGS stock trades at $9.90, down 0.9% today, with a mixed technical picture showing a bearish moving average trend but oversold RSI levels. The company reported strong Q1 2026 earnings, beating estimates with 28% revenue growth and raised full-year guidance. Analyst consensus is a Buy with a $18.00 price target, implying significant upside, though valuation ratios like a P/E of 44.91 remain elevated.
The outlook is cautiously optimistic, driven by robust revenue growth, expanding margins, and global expansion. Key risks include cost pressures from tariffs and freight, competitive threats, and the stock's high valuation requiring sustained execution. Near-term performance hinges on Q2 2026 earnings delivery against a $0.07 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
